



**CCM DUOPHARMA BIOTECH BERHAD (524271-W)**  
(Incorporated in Malaysia)  
**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**  
**FOR THE PERIOD ENDED 31 MARCH 2016**

Group	Reserves					Retained Profit RM '000	Total RM '000
	Share Capital RM '000	Treasury Shares RM' 000	Share Premium RM '000	Revaluation Surplus RM '000	Translation Reserve RM '000		
At 1 January 2016	139,478	-	194,205	0	(722)	116,757	449,718
Foreign exchange translation differences					15		15
Total other comprehensive income for the period	-	-	-	-	15	-	15
Profit for the year						7,828	7,828
Total comprehensive income for the period	-	-	-	-	15	7,828	7,843
At 31 March 2016	139,478	0	194,205	0	(707)	124,585	457,561



**CCM DUOPHARMA BIOTECH BERHAD (524271-W)**  
(Incorporated in Malaysia)  
**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**  
**FOR THE PERIOD ENDED 31 MARCH 2016**

Group	Reserves					Retained Profit RM '000	Total RM '000
	Non-distributable						
	Share Capital RM '000	Treasury Shares RM' 000	Share Premium RM '000	Revaluation Surplus RM '000	Translation Reserve RM '000		
At 1 January 2015	69,739	(1,578)	13,720	-	-	111,749	193,630
Foreign currency translation differences for foreign operations	-	-	-	-	(722)	-	(722)
Total comprehensive income for the period	-	-	-	-	-	36,391	36,391
Total comprehensive income for the period	69,739	(1,578)	13,720	-	(722)	148,140	229,299
Re-issuance of all treasury shares in open market		1,578	594				2,172
Distribution cost on reissuance of all treasury share in open market			(8)				(8)
2014 final dividend (14.5 sen per share tax exempt under single tier system)						(20,225)	(20,225)
2015 interim dividend (4 sen per share tax exempt under single tier system)						(11,158)	(11,158)
Issuance of ordinary shares pursuant to Right Issue exercise	69,739		181,324				251,063
Distribution cost pursuant to Right Issue exercise (net of tax)			(1,425)				(1,425)
At 31 December 2015	139,478	0	194,205	0	(722)	116,757	449,718

(The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2015 and the accompanying explanatory notes attached to the interim financial statements.)



**CCM DUOPHARMA BIOTECH BERHAD (524271-W)**  
(Incorporated in Malaysia)  
**UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT**  
**FOR THE PERIOD ENDED 31 MARCH 2016**

	<b>31 March 2016</b>	<b>31 March 2015</b>
	<b>RM '000</b>	<b>RM '000</b>
<b>Cash flows from operating activities</b>		
Profit before taxation	9,941	12,198
Adjustments for:		
Depreciation of property, plant and equipment	5,510	2,139
Interest income	(1,222)	(79)
Finance costs	1,472	41
<i>Operating profit before changes in working capital</i>	15,701	14,299
Change in inventories	(12,961)	(1,092)
Change in receivables, deposits and prepayments	3,726	401
Change in payables and accruals	3,031	4,801
<i>Cash generated from operations</i>	9,497	18,409
Finance costs paid	(1,472)	(41)
Interest income	1,222	79
Income tax paid	(1,844)	(2,234)
Net cash generated from operating activities	7,403	16,213
<b>Cash flows from investing activities</b>		
Acquisition of property, plant and equipment	(4,011)	(6,203)
Cost associated to conversion of land to industrial status		
Proceed from disposal of property, plant and equipment		
Proceed from issuance of shares		2,172
Net cash used in investing activities	(4,011)	(4,031)
<b>Cash flows from financing activities</b>		
Net cash used in financing activities	-	-
Net increase in cash and cash equivalents	3,392	12,182
Cash and cash equivalents at 1 January	143,510	18,303
Cash and cash equivalents as at 31 March	146,902	30,485
-		
<b>(l) Cash and cash equivalents comprise:</b>		
	<b>RM '000</b>	<b>RM '000</b>
Cash and bank balances	24,665	23,310
Deposits placed with licensed financial institutions	122,237	7,175
	146,902	30,485

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2015 and the accompanying explanatory notes attached to the interim financial statements.)